Benegut® - Digestive Comfort

Benegut® is a patented botanical extract from shiso leaves (Perilla frutescens), developed to support digestive comfort. Benegut® contributes to normal gastrointestinal function and intestinal barrier integrity, helping to improve overall intestinal comfort. Supported with both acute and chronic clinical trials. 300 mg/day.

DOWNLOAD THE BROCHURE

Benegut® - Key features

  • Patented botanical extract from shiso leaves

  • Contributes to intestinal barrier integrity and normal gastrointestinal function

  • Helps reduce sensation of bloating and feeling of fullness

  • Supports digestive comfort

Science supporting Benegut®

Benegut® is designed to support digestive comfort in subjects experiencing gastrointestinal discomfort.
Its effects on gastrointestinal smooth muscle function and intestinal barrier integrity have been investigated through in vitro and in vivo studies, providing mechanistic insight into its role in digestive comfort.

The clinical findings of Benegut® are supported by both chronic and acute human clinical studies, demonstrating outcomes relevant to gastrointestinal comfort.

Characterisation

Benegut® is a patented botanical extract obtained by water extraction of shiso leaves (Perilla frutescens L.), an annual edible herbaceous plant harvested on the island of Hokkaido in Japan. Benegut® is standardised on a special flavonoid fraction and its key active ingredient Vicenin 2 and on rosmarinic acid, determined by HPLC.

Bioactive compounds
    Rosmarinic acid                  ≥ 0.05%
    Special flavonoids fraction   ≥ 0.18%
                     incl. Vicenin-2   ≥ 0.007%

Composition: Shiso leaf extract (Perilla Frutescens L.)

Recommended daily dosage: 300 mg

Clinically supported benefits

Benegut® is supported by a double‑blind, randomised, placebo‑controlled clinical study, showing a contribution to reduced gastrointestinal discomfort over time.

Double-blind, randomised, placebo-controlled study.

LOCATIONS

Esslingen, Germany
BioTeSys GmbH
YEAR & DURATION 2012
4 weeks
POPULATIONS

50 subjects
41 women & 9 men
Age: 30-70 years old
BMI: 19-30 kg/m2
Healthy subjects with gastrointestinal discomfort evaluated by a questionnaire
PROTOCOLS

Baseline  –  Run-in Phase (2 weeks)
Supplementation – Intervention phase (4 weeks) divided in: Visit 1 (0-15 days) & Visit 2 (15-30 days)

Gastrointestinal symptoms: Bloating/distension, passage of gas, GI rumbling, feeling of fullness, abdominal discomfort
on a Likert scale from 0 to 4

Confounding factors monitored: Perceived stress PSQ20 score; stool frequency  
INTAKES

CAPSULES
2 x 150 mg/day

 

After 4 weeks of supplementation, all assessed criteria related to digestive comfort showed statistically significant changes following Benegut® consumption, contributing to:

  • a reduced passage of gas
  • a reduced sensation of gastrointestinal rumbling
  • an improved perception of fullness
  • overall abdominal comfort



Benegut® supports digestive comfort, with effects observed after a single intake in a clinical setting. 

Its effects were evaluated in an acute, double‑blind, randomised, powered cross‑over study.

LOCATIONS Esslingen, Germany
BioTeSys GmbH
YEAR & DURATION 2022
Acute study, assessment over 90 minutes
POPULATIONS

30 healthy adult subjects
Age: 18-30 years old
BMI: 19-30 kg/m2
PROTOCOLS

Gastrointestinal discomfort assessed after a high‑caloric meal using a visual analogue scale (VAS, 0–10) and Likert scales
INTAKES

ORODISPERSIBLE STICK PACKS
300 mg of Benegut or placebo taken immediately after meal

Following supplementation with Benegut®, statistically significant changes in overall gastrointestinal comfort were observed 90 minutes after a high‑caloric meal, compared with control conditions.


Feeling of fullness, bloating and burping were the three main endpoints contributing to the observed changes in gastrointestinal comfort.

         

Benegut® is safe.

No adverse event linked to Benegut® supplementation has been recorded.

Certifications & Compliance

Non-GMO, Halal, Kosher, gluten-free, suitable for vegetarians

References

CLINICAL TRIALS
2023 Publication pending
Buchwald-Werner S. et al. BMC Complement Altern Med. 2014; 14:173

MECHANISTIC STUDIES
Verspohl J. et al. Phytomedicine. 2013; 427–431
Buchwald-Werner S. et al. Agro Food Industry Hi Tech. 2016; vol. 27(5)

PATENT
EP2599488A1. Vicenin 2 and derivatives thereof for use as antispasmodic and/or prokinetic agent.

TRADEMARKS
The trademark Nutrigut® must be used for the following territories: Argentina, Australia, European Union, New Zealand, Switzerland, Turkey, Ukraine.

DOWNLOAD THE BROCHURE

This website is intended to provide information about Biotexia’s ingredients, used in various food/dietary supplement products around the world. It is only intended for business to business and to provide information to food/dietary supplement professionals and is not designed for the general public. Statements used on this website have not been evaluated by competent authority. Products are not intended to diagnose, treat, cure or prevent any disease.